Attenuation by 4-aminopyridine of delayed vasorelaxation by troglitazonePEULER, Jacob D; WARFIELD, R. K. N; PHELPS, Laura E et al.Metabolism, clinical and experimental. 2004, Vol 53, Num 2, pp 147-152, issn 0026-0495, 6 p.Article

Sequence variation in PPARG may underlie differential response to troglitazoneWOLFORD, Johanna K; YEATTS, Kimberly A; DHANJAL, Sharanjeet K et al.Diabetes (New York, NY). 2005, Vol 54, Num 11, pp 3319-3325, issn 0012-1797, 7 p.Article

Troglitazone : the lesson that nobody learned?GALE, Edwin A. M.Diabetologia (Berlin). 2006, Vol 49, Num 1, pp 1-6, issn 0012-186X, 6 p.Article

Troglitazone and liver injury: In search of answersCHOJKIER, Mario.Hepatology (Baltimore, Md.). 2005, Vol 41, Num 2, pp 237-246, issn 0270-9139, 10 p.Article

Evaluation of solid state form of troglitazone by solid state NMR spectroscopySUZUKI, Nobuyuki; KAWASAKI, Takao.Journal of pharmaceutical and biomedical analysis. 2005, Vol 37, Num 1, pp 177-181, issn 0731-7085, 5 p.Article

Troglitazone causes acute mitochondrial membrane depolarisation and an AMPK-mediated increase in glucose phosphorylation in muscle cellsKONRAD, D; RUDICH, A; BILAN, P. J et al.Diabetologia (Berlin). 2005, Vol 48, Num 5, pp 954-966, issn 0012-186X, 13 p.Article

Improvement of insulin resistance by troglitazone ameliorates cardiac sympathetic nervous dysfunction in patients with essential hypertension. CommentaryWATANABE, Kouki; KOMATSU, Jiroh; KURATA, Makoto et al.Journal of hypertension. 2004, Vol 22, Num 9, pp 1671-1672, issn 0263-6352, 10 p.Article

Direct toxicity effects of sulfo-conjugated troglitazone on human hepatocytesSAHA, Sudipta; LEE SUN NEW; HAN KIAT HO et al.Toxicology letters. 2010, Vol 195, Num 2-3, pp 135-141, issn 0378-4274, 7 p.Article

Synthesis of new troglitazone derivatives: Anti-proliferative activity in breast cancer cell lines and preliminary toxicological studySALAMONE, Stéphane; COLIN, Christelle; GRILLIER-VUISSOZ, Isabelle et al.European journal of medicinal chemistry. 2012, Vol 51, pp 206-215, issn 0223-5234, 10 p.Article

Liver enzyme monitoring in patients treated with troglitazoneGRAHAM, David J; DRINKARD, Carol R; SHATIN, Deborah et al.JAMA, the journal of the American Medical Association. 2001, Vol 286, Num 7, pp 831-833, issn 0098-7484Article

Ontology-based knowledge management of troglitazone-induced hepatotoxicityHUG, Hubert; DANNECKER, Robert; SCHINDLER, Richard et al.Drug discovery today. 2004, Vol 9, Num 22, pp 948-954, issn 1359-6446, 7 p.Article

Effects of troglitazone in young first-degree Relatives of patients with type 2 diabetesLEVIN, Klaus; HOTHER-NIELSEN, Ole; HENRIKSEN, Jan Erik et al.Diabetes care. 2004, Vol 27, Num 1, pp 148-154, issn 0149-5992, 7 p.Article

RESEARCH PAPER Troglitazone induces cytotoxicity in part by promoting the degradation of peroxisome proliferator-activated receptor γ co-activator-1α proteinXUEMEI LIAO; YANFEI WANG; WONG, Chi-Wai et al.British journal of pharmacology. 2010, Vol 161, Num 4, pp 771-781, issn 0007-1188, 11 p.Article

Effect of BMI and age on adipose tissue cellularity and differentiation capacity in womenVAN HARMELEN, V; SKURK, T; RÖHRIG, K et al.International journal of obesity. 2003, Vol 27, Num 8, pp 889-895, issn 0307-0565, 7 p.Article

TroglitazoneYOKOI, Tsuyoshi.Handbook of experimental pharmacology. 2010, Vol 196, pp 419-435, issn 0171-2004, 17 p.Article

Pilot study of prescription-event monitoring in Japan comparing troglitazone with alternative oral hypoglycemicsKUBOTA, Kiyoshi; KAWABE, Eri; HINOTSU, Shiro et al.European journal of clinical pharmacology. 2001, Vol 56, Num 11, pp 831-838, issn 0031-6970Article

Mechanism of troglitazone action in type 2 diabetesPETERSEN, K. F; KRSSAK, M; INZUCCHI, S et al.Diabetes (New York, NY). 2000, Vol 49, Num 5, pp 827-831, issn 0012-1797Article

Troglitazone, an antidiabetic agent, inhibits cholesterol biosynthesis through a mechanism independent of peroxisome proliferator-activated receptor-γMINGHAN WANG; WISE, S. C; LEFF, T et al.Diabetes (New York, NY). 1999, Vol 48, Num 2, pp 254-260, issn 0012-1797Article

The PPAR-γ agonist troglitazone antagonizes survival pathways induced by STAT-3 in recombinant interferon-β treated pancreatic cancer cellsVITALE, Giovanni; ZAPPAVIGNA, Silvia; PICCOLETTI, Roberta et al.Biotechnology advances. 2012, Vol 30, Num 1, pp 169-184, issn 0734-9750, 16 p.Article

Evaluation of solid dispersions on a molecular level by the Raman mapping techniqueFURUYAMA, Naho; HASEGAWA, Susumu; HAMAURA, Takeshi et al.International journal of pharmaceutics. 2008, Vol 361, Num 1-2, pp 12-18, issn 0378-5173, 7 p.Article

Carcinogenic susceptibility of rasH2 mice to troglitazoneJIN, Meilan; TAKAHASHI, Miwa; MOTO, Mitsuyoshi et al.Archives of toxicology. 2007, Vol 81, Num 12, pp 883-894, issn 0340-5761, 12 p.Article

Les études de prévention médicamenteuse du diabète de type 2 doivent-elles nous amener à changer nos prescriptions ? = Should type diabetes prevention pharmacological studies prompt us to change our prescription habitsBLICKE, J. F.Diabetes & metabolism. 2003, Vol 29, Num 5, pp 547-553, issn 1262-3636, 7 p.Article

Actions of peroxisome proliferator -activated receptors-γ agonists explaining a possible blood pressure-lowering effectSARAFIDIS, Panteleimon A; LASARIDIS, Anastasios N.American journal of hypertension. 2006, Vol 19, Num 6, pp 646-653, issn 0895-7061, 8 p.Article

Troglitazone, a Ligand of Peroxisome Proliferator-Activated Receptor-γ, Stabilizes NUCB2 (Nesfatin) mRNA by Activating the ERK1/2 Pathway: Isolation and Characterization of the Human NUCB2 GeneYAMADA, Masanobu; HORIGUCHI, Kazuhiko; MORI, Masatomo et al.Endocrinology (Philadelphia). 2010, Vol 151, Num 6, pp 2494-2503, issn 0013-7227, 10 p.Article

Metabolic activation of troglitazone: Identification of a reactive metabolite and mechanisms involvedKAN HE; TALAAT, Rasmy E; POOL, William F et al.Drug metabolism and disposition. 2004, Vol 32, Num 6, pp 639-646, issn 0090-9556, 8 p.Article